Leerink Partners
Tracked across 22 events · 817 articles · First seen May 16, 2025 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Leerink Partners served as joint book-running manager, benefiting from underwriting fees and strengthening its healthcare franchise.
Aug 05, 2026 · 15 articles
Business
Impact: Leerink Partners served as a lead book-running manager, generating underwriting revenue and reinforcing its expertise in healthcare IPOs. The deal enhances its reputation in the sector.
Aug 07, 2026 · 8 articles
Business
Impact: Leerink Partners is acting as the sole bookrunning manager for Amanat Acquisition Corporation's IPO, responsible for managing the offering.
May 19, 2026 · 6 articles
Business
Impact: Leerink Partners is acting as a joint bookrunning manager for the public offering by Tango Therapeutics, assisting in the sale of securities.
Jun 08, 2026 · 8 articles
Business
Impact: Leerink Partners acted as a joint book-running manager for Kailera Therapeutics's IPO, facilitating the offering and earning underwriting fees.
Apr 16, 2026 · 8 articles
Business
Impact: Leerink Partners is acting as a joint book-running manager for Trevi Therapeutics' public offering.
Apr 16, 2026 · 7 articles
Business
Impact: Leerink Partners is a joint book-running manager, participating in the offering and earning fees.
Aug 04, 2026 · 6 articles
Business
Impact: Leerink Partners is acting as an active book-running manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
Business
Impact: Leerink Partners is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
Business
Impact: Leerink Partners acted as a joint book-running manager for the IPO, earning fees and enhancing its reputation in biotech capital markets.
Jul 06, 2026 · 25 articles
Business
Impact: Leerink Partners is hosting the Therapeutics Forum where Immunic will have one-on-one meetings.
Jul 09, 2026 · 8 articles
Business
Impact: Served as lead financial advisor to XOMA Royalty.
Jul 14, 2026 · 6 articles
Business
Fulcrum Therapeutics and Slate Medicines have signed a definitive all-stock merger agreement to create a combined company focused on next-generation migraine treatments. The combined entity will operate as Slate Medicines and trade on Nasdaq under…
Impact: Leerink Partners acted as financial advisor to Fulcrum Therapeutics in the merger.
Aug 17, 2026 · 6 articles
Business
Impact: Leerink Partners has a neutral rating and a $131 price target, citing regulatory and technology uncertainties.
Jun 18, 2026 · 319 articles
Business
Impact: Leerink Partners served as exclusive financial advisor to Obsidian Therapeutics, Inc. and acted as a placement agent for the private placement financing.
Apr 14, 2026 · 7 articles
Business
Impact: Leerink Partners>>> served as an advisor to GSK plc>>> in the acquisition.
Jun 09, 2026 · 56 articles
Business
Impact: Leerink Partners is a research firm whose analyst, Craig Moffett, offered a measured reception to the Siri AI updates.
May 19, 2026 · 254 articles
Business
Impact: Investment bank; previously commented on Palsonify's approval.
Jul 06, 2026 · 34 articles
Regulatory
Impact: Leerink analyst Andrew Berens commented that the launch delay was not anticipated.
Jul 17, 2026 · 7 articles
Business
Impact: Leerink Partners is the firm where Craig Moffett, an analyst commenting on Verizon's restructuring, is employed.
Nov 13, 2025 · 11 articles
Business
Impact: Leerink Partners provided analyst commentary on the acquisitions.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Leerink Partners live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard